Successful SCT for Nijmegen breakage syndrome

Nijmegen breakage syndrome (NBS) is characterized by chromosomal instability, radiation hypersensitivity, characteristic facial appearance, immunodeficiency and strong predisposition to lymphoid malignancy. Traditionally, NBS patients have not undergone hematopoietic SCT (HSCT) owing to concerns abo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Albert, Michael (VerfasserIn) , Gennery, A. R. (VerfasserIn) , Greil, Johann (VerfasserIn) , Cale, C. M. (VerfasserIn) , Kalwak, K. (VerfasserIn) , Kondratenko, I. (VerfasserIn) , Mlynarski, W. (VerfasserIn) , Notheis, G. (VerfasserIn) , Führer, M. (VerfasserIn) , Schmid, I. (VerfasserIn) , Belohradsky, B. H. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2010
In: Bone marrow transplantation
Year: 2010, Jahrgang: 45, Heft: 4, Pages: 622-626
ISSN:1476-5365
DOI:10.1038/bmt.2009.207
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bmt.2009.207
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bmt2009207
Volltext
Verfasserangaben:M.H. Albert, A.R. Gennery, J. Greil, C.M. Cale, K. Kalwak, I. Kondratenko, W. Mlynarski, G. Notheis, M. Führer, I. Schmid and B.H. Belohradsky
Beschreibung
Zusammenfassung:Nijmegen breakage syndrome (NBS) is characterized by chromosomal instability, radiation hypersensitivity, characteristic facial appearance, immunodeficiency and strong predisposition to lymphoid malignancy. Traditionally, NBS patients have not undergone hematopoietic SCT (HSCT) owing to concerns about increased toxicity. We therefore report on the HSCT experience in NBS patients in Europe. Six patients were transplanted either for resistant or secondary malignancy (four patients) or severe immunodeficiency (two patients). Five patients received reduced-intensity conditioning regimens. After a median follow-up of 2.2 years, five patients are alive and well. One patient who received myeloablative conditioning died from sepsis before engraftment. Acute GVHD grades I-II occurred in three of five patients, mild chronic GVHD in one. All five surviving patients exhibit restored T-cell immunity. The experience in these six patients suggests that HSCT in NBS is feasible, can correct the immunodeficiency and effectively treat malignancy. Acute toxicity seems to be reasonable with reduced-intensity conditioning regimens.
Beschreibung:Online verfügbar 17 August 2009
Gesehen am 16.11.2022
Beschreibung:Online Resource
ISSN:1476-5365
DOI:10.1038/bmt.2009.207